VivoSeq
Metabolic & Endocrine

Primary Hyperparathyroidism

11

Pipeline Programs↗

1

Active Trials↗

5

Companies Involved↗

Primary Hyperparathyroidism is an emerging landscape with 11 programs across 5 companies. The most active players are Kyowa Kirin Co., Ltd., Hyundai Pharmaceutical Co., LTD., Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 5 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

0/100

Mech. Concentration

17/100

Completion Rate

90/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Kyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.

1 program

Phase 3H

Hyundai Pharmaceutical Co., LTD.

1 program

Phase 3P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 3Pfizer logo

Pfizer

1 program

ApprovedAmgen logo

Amgen

5 programs

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

14 of 16 classified programs — the dominant modality here.

13%ALL OTHERSMonoclonal antibody213%

Small molecule leads; the ring shows all 16 classified programs, each share of the total. Modality classified for 100% of 16 pipeline programs.

Analysis

Trial Status

23

clinical trials

Completed18 · 78%
Unknown status2 · 9%
Terminated1 · 4%
Recruiting1 · 4%
Withdrawn1 · 4%

Clinical Trials

Trial Activity

23 trials

Bisphosphonate Prior to Parathyroidectomy in Primary Hyperparathyroidism
Recruiting·UUniversity of Aarhus·Phase 4·NCT06859580·140 enrolled
Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate
Completed·MMedical University of Vienna·Phase 4·NCT01222026·63 enrolled
Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism
Completed·—·Phase 2/3·NCT02525796·69 enrolled
An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism
Completed·Kyowa Kirin Co., Ltd. logoKyowa Kirin Co., Ltd.·Phase 3·NCT01460030
Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions?
Completed·KKarolinska University Hospital·N/A·NCT02227264·110 enrolled
A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism
Completed·Amgen logoAmgen·Phase 2·NCT00936988·45 enrolled
A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT)
Completed·Amgen logoAmgen·Phase 2·NCT00936650·78 enrolled
PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice
Completed·Amgen logoAmgen·N/A·NCT00928408·305 enrolled
Effect of Vitamin D Treatment in Primary Hyperparathyroidism
Completed·UUniversity of Aarhus·Phase 2/3·NCT00674154·46 enrolled
Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism
Completed·—·Phase 4·NCT02417389·22 enrolled
Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.
Completed·—·Phase 3·NCT03027557·46 enrolled
Safety, Tolerability, and Clinical Effects of Twice-daily Doses of Cinacalcet (AMG 073) in Adults With Primary Hyperparathyroidism (HPT)
Completed·Amgen logoAmgen·Phase 2·NCT03776058·10 enrolled
Vitamin D Repletion in Primary Hyperparathyroidism
Completed·—·Phase 4·NCT01306656·9 enrolled
Effects of Vitamin D Replacement in Patients With Primary Hyperparathyroidism (PHPT)
Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00538720·22 enrolled
OPG/Soluble RANKL (sRANKL) and Bone Mineral Density in Primary Hyperparathyroidism
Completed·WWroclaw Medical University·N/A·NCT01889134·112 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)